tbuckley/cabot-search huggingface dataset:
Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.
Authors: Javier Cortes, Ahmad Awada, Peter Andrew Kaufman, Louise Yelle, Edith A. Perez, Galina Velikova, Jantien Wanders, Martin S. Olivo, Yi He, Corina Dutcus, W. Robert Simons, Christopher Twelves
Journal: Journal of Clinical Oncology (2013)

1050^ Background: In a phase III trial comparing eribulin (E) vs. capecitabine (C) in pts with locally advanced or MBC, a trend for improved OS was observed but a statistically significant superiority was not demonstrated with E vs. C for OS or PFS. The AE profiles were consistent with known side effects. We now report QoL results from this trial. Methods: Pts received eribulin mesylate 1.4 mg/m 2 on Days 1 and 8, or C 1.25 g/m 2 BID orally on Days 1-14, of a 21-day cycle. Eligible pts had received prior therapy including an anthracycline and taxane, and were receiving study drug as 1 st -, 2 nd -, or 3 rd -line therapy for advanced disease. QoL, a secondary objective, was assessed using EORTC QLQ-C30 and QLQ-BR23 questionnaires at baseline, 6 weeks, 3, 6, 12, 18, and 24 months after starting treatment (or until progressive disease or treatment change), and at unscheduled visits. Longitudinal analyses were carried out using weighted generalized estimating equations adjusted for non-random attrition due to death within 12 months. Model covariates were time (visit), region, and baseline QoL. The primary endpoint was change from baseline for Global Health Status (GHS)/overall QoL; exploratory endpoints were change from baseline for each functional domain, and signs/symptoms. Results: 1,102 pts were randomized (E 554; C 548). GHS/QoL scores were low at baseline for E (56.3) and C (54.7) on a scale of 0 (worse) to 100 (best). GHS/QoL and cognitive functioning improved significantly more in pts receiving E vs. C, (6.5 [p=0.048] and 15.3 [p&lt;0.001], respectively). Emotional functioning improved significantly for pts receiving C vs. E (3.3; p=0.033). Pain was comparable at baseline, and was lower at subsequent visits with both treatments. Patient-reported signs/symptoms in favor of E included nausea and vomiting (E1.9; p=0.043) and diarrhea (-3.7; p=0.001); systemic side effects (5.2; p&lt;0.001) and upset by hair loss (9.3; p=0.023) favored C. Conclusions: GHS/QoL scores improved more in pts receiving E than C. E showed advantages in terms of gastrointestinal effects while C had advantages in relation to hair loss. Clinical trial information: NCT00337103.
Gender differences in survival from cutaneous melanoma: Analysis of United States SEER data, 1992 to 2009.
Authors: Roxana Stefania Dronca, Amy Weaver, Jerry D. Brewer, Lynne T Shuster, Lisa A. Kottschade, Shane Young Morita, Svetomir Markovic
Journal: Journal of Clinical Oncology (2013)

9073 Background: An accumulating body of evidence suggests that the outcome of early-stage melanoma is influenced by endocrine and menopausal status. However, it remains controversial as to whether the superior female melanoma-specific survival (MSS) is restricted to early stage disease or if it also pertains to patients with metastatic melanoma (MM). Methods: We analyzed data from the 13 registries that participate in the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program. We identified all cases of primary invasive melanoma diagnosed between 1992 and 2009; none of the patients had a prior history of another cancer. MSS was compared between males and females, stratified by stage of disease. Age groups were defined as 18-45y, 46-54y, 55-64y, 65+y as a proxy of female menopausal status. Results: The study population included 87,165primary invasive melanoma cases (unstaged n=2834). MSS was significantly poorer for males compared to females for localized (n=72,456) and regional (n=8,945) disease for all age groups (Hazard ratio (HR) ranging from 1.21 to 2.09, all p&lt;0.001). MSS was not significantly different between males and females for patients with distant disease at diagnosis (n= 2930; HR 0.99, 0.92, 1.11, 1.07 for each age group) and remained non-significant after adjusting for Breslow thickness, histologic subtype, anatomic site, and age group (adjusted HR 1.04 males vs. females; 95% CI 0.95-1.14; p=0.41). Conclusions: While our results were consistent with earlier reports that women have higher MSS rates compared to men for early (stage I-III) melanoma, the intriguing finding of this study was that the female survival advantage does not vary with age or menopausal status as compared to men, which is contrary to previously published reports. Furthermore, we found that the difference in survival was no longer significant for patients with MM, suggesting that sex may influence local and regional, but not distant cancer progression.
T1 MAPPING AND MYOCARDIUM STRAIN EVALUATED THROUGH TISSUE TRACKING IN PATIENTS WITH LYMPHOMA TREATED WITH ANTHRACYCLINES
Authors: Isabela Costa, Bruna Leal, Cecilia Cruz, Juliana Pereira, Carlos Eduardo Rochitte, Roberto Kalil Filho, Ludhmila Abrahão Hajjar
Journal: Journal of the American College of Cardiology (2020)
TIME TO ADVERSE EVENT IN TYPE A ACUTE AORTIC DISSECTION PATIENTS FOLLOWING LIMITED ASCENDING REPLACEMENT
Authors: Carsten Opris, Himanshu J. Patel, Davide Pacini, Carlo De Vincentiis, Thomas G. Gleason, Anthony Estrera, Nimesh Desai, Melissa Levack, Daniel G. Montgomery, Christoph Nienaber, George Arnaoutakis, Bradley Taylor, Kevin Greason, Valerio Tolva, Takeyoshi Ota, Marek Ehrlich, Kim Eagle
Journal: Journal of the American College of Cardiology (2020)
MULTIPLE HORMONAL AND METABOLIC DEFICIENCY SYNDROME REDUCES SURVIVAL IN CHRONIC HEART FAILURE: THE TOSCA REGISTRY
Authors: Alberto Marra, Eduardo Bossone, Andrea Salzano, Massimo Iacoviello, Giuseppe Rengo, Francesco Cacciatore, Giuseppe Limongelli, Francesco Perticone, Pasquale Perrone-Filardi, Antonio Mancini, Maurizio Volterrani, Olga Vriz, Roberta D'Assante, Toru Suzuki, Hector Ventura, Antonio Cittadini
Journal: Journal of the American College of Cardiology (2020)
The clinical and biologic impact of PPP6C mutations in melanoma.
Authors: Heidi L. Gold, Jordan Wengrod, Jiaying Tian, Eleazar Vega-Saenz de Miera, Zaineb Nadeem, Nathaniel H. Fleming, Richard Shapiro, Eva Hernando-Monge, Lawrence Gardner, Iman Osman
Journal: Journal of Clinical Oncology (2013)

9067 Background: PP6C binds to regulatory units to affect a number of important pathways including cell proliferation and DNA repair. Recently two independent groups reported for the first time the presence of somatic mutations in the PPP6C gene in ~10% of short term cultures and limited number of human melanoma tissues. However, the clinical or biological relevance of PPP6C mutations in melanoma patients is unknown. Our objectives were to examine the clinical relevance of PPP6C mutations in a well characterized cohort of melanoma specimens linked to extensive, prospectively-collected clinical information and to explore the functional consequence of different categories of mutations. Methods: Sanger dideoxy sequencing was performed on PCR-amplified DNA from macro-dissected FFPE tumors. Associations between PPP6C mutations and baseline characteristics, recurrence, survival, and BRAF/ NRAS mutational status were examined. The impact of mutations on binding PP6C regulatory units was assessed as well as the effect on additional downstream pathways. Results: 308 primary melanoma patients (118 Stage I, 92 Stage II, and 98 Stage III) were examined (median follow up: 5.3 years). 50 PPP6C mutations in 33 patients (10.7%) were identified with 11 tumors harboring more than one mutation. One mutation (R301C) was identified in 6 patients. PPP6C mutations occurred with similar frequencies across stages and showed no association with BRAF or NRAS mutations. Mutations were categorized into 3 groups: Mutations resulting in premature stop codon (n=9), those occurring in the active site (n=16) and others (n=8). 8/9 (89%) patients with stop mutations recurred and developed visceral metastases. Functional studies revealed that PPP6C mutants also behaved differently; some PPP6C mutations led to decreased binding to regulatory subunits, others, including the R301C mutation did not. Conclusions: Our data suggest that PPP6C mutation is an early event in melanoma progression and independent of BRAF or NRAS mutations. Data also suggest different biologic and clinical impact of PPP6C mutations, with stop mutations showing association with development of visceral metastases that requires further clinical and functional study.
BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE)
Authors: John R. Teerlink, Rafael Diaz, G. Michael Felker, John McMurray, Marco Metra, Scott D. Solomon, Jason Legg, Claire Varin, Christopher Kurtz, Fady Malik, Siddique A. Abbasi
Journal: Journal of the American College of Cardiology (2020)
Amplification of HER-2/neu (erbB2) gene expression in gallbladder (GBC) and in bile duct cancer (BDC) (biliary tract cancer, BTC)
Authors: T. Kawamoto, M. Thomas, E. Tarco, S. Trivedi, I. Wistuba, S. Krishnamurthy
Journal: Journal of Clinical Oncology (2006)

4011 Background: GBC and BDC (BTC) are uncommon in the United States, but are endemic in parts of South America and Asia. BTC are aggressive tumors with poor survival rates. Chemotherapy RR is &lt;30%, and no survival benefit has been demonstrated. Improved understanding of the molecular carcinogenic mechanisms of BTC may lead to improved therapeutic regimens. Activation of HER-2/neu play a prominent role in the development of breast cancer. In this study, BTC patient (pt) specimens from the U.S., Chile, and Japan were examined the HER-2/neu immunohistochemical (IHC) expression and its gene amplification by fluorescence in situ hybridization (FISH). Methods: Specimens from 26 GBC patients (Chile, US), 12 BDC (USA), 6 cholecystitis (Chole.) (Japan) and 7 normal GB (Chile) were examined. pStage (AJCC) of the pt was: IA: 2, IB: 9, IIA: 7, IIB: 9, III: 3, IV: 4, unknown: 4. Histologic grade was G1 and G2 adenocarcinoma (adca): 22, G3 adca: 13, squamous cell carcinoma: 1, unknown: 2. All cases were screened for HER-2/neu by IHC (0–3+). HER-2/neu gene amplification (FISH (+)) (defined as a HER-2/CEP17 ratio of 2.0 or greater) was performed by double color Her-2/neu gene/chromosome 17 centromere (CEP17) FISH assays using PathVysion HER-2/neu DNA probe kit. Results: In BTC, HER-2/neu IHC 0, 1+, 2+ and 3+ scores were found in 0 (0%), 20 (53%), 11 (29%) and 7 (18%), respectively. In Chole., 3 of 6 (50%) showed 1+ while the remaining and normal GB were all negative for IHC. FISH on paraffin sections was considered successful on 36 (95%) of the 38 cases. HER-2/neu FISH (+) was detected in 7 of 36 (19%) (6 from 3+ cases and 1 from 2+ case) and none in Chole. and normal GB. There was a significant correlation between overexpression by IHC (2+ and 3+) and FISH (+) (Fisher’s exact test; P=0.0123), but no significant correlation between pStage, histologic grade and FISH (+). Conclusions: The HER-2/neu amplification was identified in 19% of BTC in comparison with the other organ cancer (breast cancer:20–25%, lung cancer: 4.5%, colorectal cancer; 2.4%, prostate cancer: 9.3%). There was a strong correlation between IHC overexpression and FISH (+). These data support therapeutic approaches using HER-2/neu targeted agents in BTC pt. HER-2/neu IHC may be a useful surrogate for its gene amplification. No significant financial relationships to disclose.
A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.
Authors: Ian E. Krop, Cristina Saura, Jordi Rodon Ahnert, Carlos Becerra, Carolyn D. Britten, Steven J. Isakoff, David Demanse, Wolfgang Hackl, Cornelia Quadt, Antonio P. Silva, Howard A. Burris, Maysa M. Abu-Khalaf, José Baselga
Journal: Journal of Clinical Oncology (2012)

508 Background: Alterations in the PI3K/AKT/mTOR pathway have been implicated in resistance to trastuzumab (T) in HER2+ breast cancer. BEZ235, a potent oral dual PI3K/mTORC1/2 inhibitor, has demonstrated growth inhibition and apoptosis in HER2+ breast cancer models, including those harboring PI3K pathway alterations, and with T resistance. In a Phase I study, BEZ235 was well tolerated as a single agent in pts with advanced solid tumors. The aim of this study was to determine the MTD of BEZ235 in combination with T in pts with T-resistant HER2+ metastatic breast cancer (mBC) with alterations of the PI3K pathway. Methods: Pts with T-resistant HER2+ mBC (i.e. disease progression during adjuvant therapy or metastatic disease on therapy with T) received oral BEZ235 daily, with weekly T (2 mg/kg). Pts were eligible for enrollment if a tumor sample was demonstrated to contain a molecular alteration of PIK3CA and/or PTEN. Dose escalation was guided by a Bayesian logistic regression model with overdose control. Results: As of 23 Sep 2011, 15 of the 19 enrolled pts were evaluable for dose escalation analysis. BEZ235 was evaluated at 3 dose levels: (1) 400 mg/day (3 pts); (2) 600 mg/day (6 pts); (3) 800 mg/day (10 pts), administered either in capsule form (400 mg) or in sachet form (600 mg and 800 mg). The MTD of BEZ235 in combination with T was estimated to be 600 mg/day. Observed DLTs were G3 nausea at 600 mg/day (1 pt), and G3 nausea, G3 fatigue and G3 skin rash (1 pt each) at 800 mg/day. The most frequent G3/4 adverse events (CTCAE v3.0) suspected to be related to study treatment were diarrhea (4 pts) and nausea (2 pts). No deaths related to study treatment occurred. 1 pt with lung and brain metastases had a partial response. 4 pts had disease stabilization for ≥4 cycles (16 weeks), including 1 pt with liver metastases, in whom BEZ235/T treatment resulted in disease stabilization for more than 21 cycles (84 weeks). Conclusions: BEZ235in combination with T demonstrated an acceptable safety profile in pts with HER2+ mBC and PI3K pathway alterations. Following the Bayesian model recommendation, the MTD for BEZ235 in combination with T was estimated to be 600 mg/day. The safety expansion arm is ongoing at the MTD.
LONG TERM RISK OF STROKE IN PATIENTS WITH NEW POST-OPERATIVE ATRIAL FIBRILLATION AFTER LIVER TRANSPLANTATION
Authors: Anees Enayati, Anoop Koshy, H.M. Omar Farouque, Paul J. Gow, Hui-Chen Han, Benjamin Cailes, Laurence Weinberg, Adam Testro, Han Lim, Andrew W. Teh
Journal: Journal of the American College of Cardiology (2020)
A phase I imaging and pharmacodynamic trial of CS-1008 in patients (pts) with metastatic colorectal cancer (mCRC).
Authors: Marika Ciprotti, Niall C. Tebbutt, Fook Thean Lee, Sze Ting Lee, Dave C. McKee, Graeme J. O'Keefe, Sylvia J. Gong, Geoffrey Chong, Hui Kong Gan, Wendie Hopkins, Bridget Chappell, Fiona Elizabeth Scott, Martin W. Brechbiel, Archie N. Tse, Mendel Jansen, Manabu Matsumura, Rira Watanabe, Robert A. Beckman, Jonathan Greenberg, Andrew Mark Scott
Journal: Journal of Clinical Oncology (2013)

2583 Background: Death receptor 5 (DR5) is a member of the TNFR superfamily that initiates the extrinsic apoptotic pathway. CS-1008 is a humanised, monoclonal IgG1 agonistic antibody (Ab) to human DR5 created by CDR grafting of the murine Ab TRA-8. The aim of this study was to investigate the impact of CS-1008 dose on biodistribution, quantitative tumor uptake and anti-tumor response in pts with mCRC. Methods: Pts with mCRC were treated with weekly IV CS-1008 in 5 non-sequential cohorts (Co). Different loading doses were used on days 1 and 8 (0.2 to 6 mg/kg), followed by a weekly dose of 2 mg/kg. D1 and D36 doses were trace-labeled with 111 In, followed by whole-body planar and regional SPECT imaging over 10 days. Primary endpoints: initial biodistribution, pharmacokinetic (PK) and tumor uptake following single infusion; changes in biodistribution, PK and tumor uptake following sequential doses. Secondary endpoints: tumor response; changes in tumor metabolism by FDG-PET; serum apoptosis biomarkers and tumor response markers. Results: 19 pts (median age 64 yrs; M:F 11:8; 2-6 prior chemotherapy regimens) were enrolled as follows: Co 1, n=2; Co 2, n=4; Co 3, n=5; Co 4, n=3; and Co 5, n=5. Tumor uptake was variable: 7 pts had no uptake, 11 pts had uptake in all sites of disease but liver, 1 pt showed liver uptake. Tumor uptake and PK were not affected by dose or repeated drug administration. No anti-CS-1008 Ab responses were detected. DR5 expression in archived samples did not correlate with uptake or response. 111 In‐CS‐1008 biodistribution showed gradual blood pool clearance and no abnormal uptake in normal tissue. Mean % change in SUVmax from baseline in lesions with uptake was higher than in those with no uptake. There were 8 SD, 1 PR and 10 PD. Duration of PR was 3.7 months (mo). Mean duration of SD was 4 mo. Disease control rate (SD + PR) in pts with uptake was 58% vs 28% of pts with no uptake. Lesions with no uptake were more likely to progress, with a PD risk of 3.4 times higher than those lesions with uptake. Conclusions: Tumor DR5 expression, assessed by 111 In-CS-1008 imaging, revealed real-time heterogeneous DR5 expression and appeared to be a promising predictive imaging biomarker of clinical benefit in pts with mCRC receiving CS-1008. Clinical trial information: NCT01220999.
THE EFFECT OF TRANSCATHETER MITRAL VALVE REPAIR ON SHORT-TERM MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Prasham Dave, Joseph Abunassar, Nawid Sayed, Corinne Babiolakis, Gianluigi Bisleri, Wael Abuzeid
Journal: Journal of the American College of Cardiology (2020)
Evidence informing the UK's COVID-19 public health response must be transparent
Authors: Nisreen A Alwan, Raj Bhopal, Rochelle A Burgess, Tim Colburn, Luis E Cuevas, George Davey Smith, Matthias Egger, Sandra Eldridge, Valentina Gallo, Mark S Gilthorpe, Trish Greenhalgh, Christopher Griffiths, Paul R Hunter, Shabbar Jaffar, Ruth Jepson, Nicola Low, Adrian Martineau, David McCoy, Miriam Orcutt, Bharat Pankhania, Hynek Pikhart, Allyson Pollock, Gabriel Scally, James Smith, Devi Sridhar, Stephanie Taylor, Peter W G Tennant, Yrene Themistocleous, Anne Wilson
Journal: The Lancet (2020)
SPECTRUM OF SARCOMERE AND MITOCHONDRIA-RELATED MUTATIONS ON MYOCARDIAL FIBROSIS IN HYPERTROPHIC CARDIOMYOPATHY
Authors: Eui-Young Choi, Hyemoon Chung, Chul Hwan Park, Yoonjung Kim, Se-Joong Rim, Kyung-A Lee
Journal: Journal of the American College of Cardiology (2020)
Lupeol is a novel agent for skin cancer chemoprevention: Modulation of NFκB and Akt pathways.
Authors: Hasan Mukhtar, Mohammad Saleem, Farrukh Afaq, Vaqar M. Adhami
Journal: Cancer Research (2004)

3152  Chemoprevention has come of age as an effective cancer control modality, however, the search for novel agent(s) for the armamentarium of cancer chemoprevention continues. We argue that agents capable to inhibit promotion stage of tumorigenesis with ability to intervene at more than one critical pathway in the tumorigenesis process will have greater advantage over other single-target agents. Lupeol [Lup-20 (29)-en-3 β-ol], a triterpene is the principal constituent of common fruit plants such as olive, mango, fig and medicinal herbs that have been used to treat skin aliments. Lupeol has been reported to possess a wide range of medicinal properties both under in vitro and in vivo conditions that include strong anti-oxidant, anti-mutagenic, anti-inflammatory, anti-malarial and anti-arthritic effects. Lupeol has been shown to afford protection against benzoyl peroxide induced toxicity in mouse skin. In the present study, we evaluated whether lupeol possess anti-tumor promoting effects in a mouse skin tumorigenesis model. We first determined the effect of topical application of lupeol to CD-1 mouse against 12-O-tetradecanoyl- phorbol-13-acetate (TPA)- induced conventional markers, and other novel markers of skin tumor promotion. We found that topical application of lupeol (1- 2 mg / mouse) 30 min prior to TPA (3.2 nmole/mouse) application onto the skin of CD-1 mice afforded significant inhibition, in a time and dose-dependent manner, against TPA-mediated increase in (i) skin edema and hyperplasia, and (ii) epidermal ornithine decarboxylase (ODC) activity and protein expression of ODC, cycloxygenase-2 and nitric oxide synthase. Because of the role of nuclear factor kappa B (NFκB) and phosphoinositide 3-kinase (PI3K) /Akt signaling in tumor promotion, we next determined the effect of topical application of lupeol to mouse skin against these signaling pathways. We found that lupeol treatment to mouse skin resulted in inhibition of TPA-induced (i) activation of PI3K, (ii) phosphorylation of Akt at Thr308, (iii) activation of NFκB and IKKα, and degradation of IKBα. We next assessed the effect of skin application of lupeol on TPA-induced skin tumor promotion in 7, 12-dimethybenz(a)anthracene-initiated CD-1 mouse. The animals pretreated with lupeol showed significantly reduced tumor incidence, lower tumor body burden and a significant delay in the latency period for tumor appearance. At the termination of the experiment at 28 weeks, 100% of the animals in TPA treated group exhibited 7-8 tumors / mouse whereas only 53% of the mice receiving lupeol prior to TPA treatment exhibited 1-3 tumors /mouse. These results for the first time provide evidence that lupeol possesses anti-skin-tumor promoting effects in CD-1 mouse and being capable to inhibit conventional as well as novel biomarkers of tumor promotion. We suggest that lupeol must also be evaluated in tumor models other than skin carcinogenesis.
Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer
Authors: M. Suntharalingam, T. Dipetrillo, P. Akerman, H. Wanebo, B. Daly, L. A. Doyle, M. J. Krasna, T. Kennedy, H. Safran
Journal: Journal of Clinical Oncology (2006)

4029 Background: Cetuximab is an IgG1, chimerized, monoclonal antibody that binds specifically to the epidermal growth factor receptor. Cetuximab improves survival when combined with radiation for patients with locally advanced head and neck cancer. We evaluated the safety and efficacy of the addition of cetuximab to concurrent chemoradiation for patients with esophageal and gastric cancer. Methods: Patients with adenocarcinoma or squamous cell cancer of the esophagus or stomach without distant organ metastases were eligible. Patients with locally advanced disease from mediastinal, celiac, portal and gastric lymphadenopathy were eligible. Surgical resection was not required. Clinical complete response was defined as no tumor on postreatment endoscopic biopsy. Patients received cetuximab, 400mg/m 2 week #1 then 250 mg/m 2 /week for 5 weeks, paclitaxel, 50 mg/m 2 /week, and carboplatin, AUC =2 weekly for 6 weeks, with concurrent 50.4 Gy radiation. Results: Thirty-seven patients have been entered. The median age was 61 (range of 30–87). Thirty-four have esophageal cancer and 3 have gastric cancer. Of the patients with esophageal cancer, twenty-five have adenocarcinoma and nine have squamous cell cancer. Thus far, 30 patients have completed treatment and are evaluable for toxicity. There have been no grade 4 non-hematologic toxicities and 1 pt had grade 4 neutropenia (3%). Six patients (20%) had grade 3 esophagitis. Other grade 3 toxicities included dehydration (n=5), rash (n=9), and paclitaxel/cetuximab hypersensitivity reactions (n=2). Eighteen of 27 patients (67%) have had clinical complete response. Seven pts out of 16 (43%) who have gone to surgery have had a pathologic CR. Conclusions: Cetuximab can be safely administered with chemoradiation for patients with esophageal cancer. Consistent with the data in head and neck cancer, cetuximab increases cutaneous toxicity but does not increase mucositis/esophagitis when combined with chemoradiation. Further evaluation is ongoing. [Table: see text]